Patents by Inventor Abdul Rasheed Mohammed
Abdul Rasheed Mohammed has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220409614Abstract: The present invention provides a method for treating behavioral and psychological symptoms in patient with dementia comprising administering an effective dose of pure 5-HT6 receptor antagonist, masupirdine or a pharmaceutically acceptable salt thereof either alone or in combination with an acetylcholinesterase inhibitor such as donepezil and NMDA (N-Methyl-D-aspartate) receptor antagonist, memantine. The present invention further provides use of the said compound in the manufacture of a medicament and pharmaceutical compositions comprising the said compounds intended for the treatment of the disorders described herein.Type: ApplicationFiled: December 2, 2020Publication date: December 29, 2022Applicant: SUVEN LIFE SCIENCES LIMITEDInventors: Ramakrishna NIROGI, Anil Karbhari SHINDE, Pradeep JAYARAJAN, Satish JETTA, Raghava Chowdary PALACHARLA, Santosh Kumar PANDEY, Abdul Rasheed MOHAMMED, Vijay Sidram BENADE, Vinod Kumar GOYAL, Ramkumar SUBRAMANIAN, Jyothsna RAVULA, Venkateswarlu JASTI
-
Patent number: 11278530Abstract: The present invention relates to compounds of formula (I), or their isotopic forms, stereoisomers, tautomers or pharmaceutically acceptable salt (s) thereof as muscarinic M1 receptor positive allosteric modulators (M1 PAMs). The present invention describes the preparation, pharmaceutical composition and the use of compound formula (I).Type: GrantFiled: October 26, 2018Date of Patent: March 22, 2022Assignee: Suven Life Sciences LimitedInventors: Ramakrishna Nirogi, Abdul Rasheed Mohammed, Anil Karbhari Shinde, Shankar Reddy Gagginapally, Durga Malleshwari Kancharla, Santosh Kumar Pandey, Renny Abraham, Venkateswarlu Jasti
-
Patent number: 11234979Abstract: The present invention relates to compounds of formula (I), or their isotopic forms, stereoisomers, tautomers or pharmaceutically acceptable salt (s) thereof as muscarinic M1 receptor positive allosteric modulators (M1 PAMs).Type: GrantFiled: October 17, 2018Date of Patent: February 1, 2022Assignee: Suven Life Sciences LimitedInventors: Ramakrishna Nirogi, Abdul Rasheed Mohammed, Anil Karbhari Shinde, Srinivas Ravella, Vanaja Middekadi, Vinod Kumar Goyal, Pradeep Jayarajan, Saivishal Daripelli, Venkateswarlu Jasti
-
Publication number: 20210386727Abstract: The present invention relates to new uses of a 5-HT4 receptor agonist, specifically Isopropyl-3-{5-[1-(3-methoxypropyl)piperidin-4-yl]-[1,3,4] oxadiazol-2-yl}-1H-indazole (Compound-1) or a pharmaceutically acceptable salts thereof, for the treatment of dementia due to menopause, senile dementia, cognitive deficits associated with schizophrenia, depression, chemotherapy-induced cognitive impairment, and behavioral and psychological symptoms of dementia such as apathy/indifference, agitation, aggression, depression, anxiety, irritability/lability, dysphoria, aberrant motor behavior, delusions, hallucinations, elation/euphoria, psychosis, disinhibition, sleep and night time behavior disorders or appetite and eating disorders. The present invention further provides use of the said compounds in the manufacture of medicament intended for the treatment of the disorders described herein.Type: ApplicationFiled: October 17, 2019Publication date: December 16, 2021Applicant: SUVEN LIFE SCIENCES LIMITEDInventors: Ramakrishna NIROGI, Abdul Rasheed MOHAMMED, Anil Karbhari SHINDE, Venkata Ramalingayya GRANDHI, Pradeep JAYARAJAN, Vijay BENADE, Gopinadh BHYRAPUNENI, Venkateswarlu JASTI
-
Publication number: 20210369685Abstract: The present invention relates to compounds of formula (I), or their isotopic forms, stereoisomers, tautomers or pharmaceutically acceptable salt (s) thereof as muscarinic M1 receptor positive allosteric modulators (M1 PAMs). The present invention describes the methods of preparation, pharmaceutical composition, combinations and the use of compound formula (I), their stereoisomers, isotopic forms or pharmaceutically acceptable salts thereof.Type: ApplicationFiled: November 21, 2018Publication date: December 2, 2021Applicant: SUVEN LIFE SCIENCES LIMITEDInventors: Ramakrishna NIROGI, Anil Karbhari SHINDE, Abdul Rasheed MOHAMMED, Rajesh Kumar BADANGE, Raghava Choudary PALACHARLA, Venkateswarlu JASTI
-
Patent number: 11040026Abstract: The present invention relates to compounds of formula (I), or their isotopic forms, stereoisomers, tautomers or pharmaceutically acceptable salt(s) thereof as muscarinic M1 receptor positive allosteric modulators (M1 PAMs). The present invention describes the preparation, pharmaceutical composition and the use of compound formula (I).Type: GrantFiled: August 31, 2017Date of Patent: June 22, 2021Assignee: Suven Life Sciences LimitedInventors: Ramakrishna Nirogi, Anil Karbhari Shinde, Abdul Rasheed Mohammed, Rajesh Kumar Badange, Pradeep Jayarajan, Gopinadh Bhyrapuneni, Venkateswarlu Jasti
-
Patent number: 10973831Abstract: The present invention relates to fluoropiperidine compounds of formula (I), their stereoisomers, isotopic forms or pharmaceutically acceptable salts thereof as 5-HT6 receptor antagonists. In particular the present invention discloses the methods of preparation, pharmaceutical composition, combinations and use of fluoropiperidine compounds, their stereoisomers, isotopic forms or pharmaceutically acceptable salts thereof.Type: GrantFiled: August 6, 2018Date of Patent: April 13, 2021Assignee: SUVEN LIFE SCIENCES LIMITEDInventors: Ramakrishna Nirogi, Anil Karbhari Shinde, Abdul Rasheed Mohammed, Rajesh Kumar Badange, Kumar Bojja, Vinod Kumar Goyal, Santosh Kumar Pandey, Jagadeesh Babu Thentu, Venkateswarlu Jasti
-
Publication number: 20200297703Abstract: The present invention relates to compounds of formula (I), or their isotopic forms, stereoisomers, tautomers or pharmaceutically acceptable salt (s) thereof as muscarinic M1 receptor positive allosteric modulators (M1 PAMs). The present invention describes the preparation, pharmaceutical composition and the use of compound formula (I).Type: ApplicationFiled: October 26, 2018Publication date: September 24, 2020Applicant: SUVEN LIFE SCIENCES LIMITEDInventors: Ramakrishna NIROGI, Abdul Rasheed MOHAMMED, Anil Karbhari SHINDE, Shankar Reddy GAGGINAPALLY, Durga Malleshwari KANCHARLA, Santosh Kumar PANDEY, Renny ABRAHAM, Venkateswarlu JASTI
-
Publication number: 20200155560Abstract: The present invention relates to fluoropiperidine compounds of formula (I), their stereoisomers, isotopic forms or pharmaceutically acceptable salts thereof as 5-HT6 receptor antagonists. In particular the present invention discloses the methods of preparation, pharmaceutical composition, combinations and use of fluoropiperidine compounds, their stereoisomers, isotopic forms or pharmaceutically acceptable salts thereof.Type: ApplicationFiled: August 6, 2018Publication date: May 21, 2020Applicant: SUVEN LIFE SCIENCES LIMITEDInventors: Ramakrishna NIROGI, Anil Karbhari SHINDE, Abdul Rasheed MOHAMMED, Rajesh Kumar BADANGE, Kumar BOJJA, Vinod Kumar GOYAL, Santosh Kumar PANDEY, Jagadeesh Babu THENTU, Venkateswarlu JASTI
-
Patent number: 10603323Abstract: The present invention relates to the combination of histamine-3 receptor inverse agonist and acetylcholinesterase inhibitor. Also, the present invention provides histamine-3 receptor (H3R) inverse agonist, or the pharmaceutically acceptable salt(s) thereof in combination with or as adjunct to acetylcholinesterase inhibitor and their use in the treatment of cognitive disorders. The present invention further provides the pharmaceutical composition containing the said combination.Type: GrantFiled: August 14, 2017Date of Patent: March 31, 2020Inventors: Ramakrishna Nirogi, Anil Karbhari Shinde, Abdul Rasheed Mohammed, Pradeep Jayarajan, Gopinadh Bhyrapuneni, Venkateswarlu Jasti
-
Publication number: 20190343812Abstract: The present invention relates to compounds of formula (I), or their isotopic forms, stereoisomers, tautomers or pharmaceutically acceptable salt(s) thereof as muscarinic M1 receptor positive allosteric modulators (M1 PAMs). The present invention describes the preparation, pharmaceutical composition and the use of compound formula (I).Type: ApplicationFiled: August 31, 2017Publication date: November 14, 2019Applicant: SUVEN LIFE SCIENCES LIMITEDInventors: Ramakrishna NIROGI, Anil Karbhari SHINDE, Abdul Rasheed MOHAMMED, Rajesh Kumar BADANGE, Pradeep JAYARAJAN, Gopinadh BHYRAPUNENI, Venkateswarlu JASTI
-
Publication number: 20190336509Abstract: The present invention relates to a combination of histamine-3 receptor inverse agonist, acetylcholinesterase inhibitor and NMDA receptor antagonist. Also, the present invention provides histamine-3 receptor (H3R) inverse agonist, or the 10 pharmaceutically acceptable salt(s) thereof in combination with or as adjunct to acetylcholinesterase inhibitor and N-Methyl-D-aspartate (NMDA) receptor antagonist and their use in the treatment of cognitive disorders. The present invention further provides the pharmaceutical composition containing the said combination.Type: ApplicationFiled: August 14, 2017Publication date: November 7, 2019Applicant: SUVEN LIFE SCIENCES LIMITEDInventors: Ramakrishna NIROGI, Anil Karbhari SHINDE, Abdul Rasheed MOHAMMED, Pradeep JAYARAJAN, Gopinadh BHYRAPUNENI, Venkateswarlu JASTI
-
Patent number: 10308620Abstract: The present invention relates to compound of formula (I), or stereoisomers and pharmaceutically acceptable salts as muscarinic M1 receptor positive allosteric modulators. This invention also relates to methods of preparing such compounds and pharmaceutical compositions comprising such compounds. The compounds of this invention are useful in the treatment of various disorders that are related to muscarinic M1 receptor.Type: GrantFiled: June 8, 2016Date of Patent: June 4, 2019Assignee: SUVEN LIFE SCIENCES LIMITEDInventors: Ramakrishna Nirogi, Abdul Rasheed Mohammed, Anil Karbhari Shinde, Shankar Reddy Gagginapally, Venkateswarlu Jasti
-
Publication number: 20190160075Abstract: The present invention relates to the combination of histamine-3 receptor inverse agonist and acetylcholinesterase inhibitor. Also, the present invention provides histamine-3 receptor (H3R) inverse agonist, or the pharmaceutically acceptable salt(s) thereof in combination with or as adjunct to acetylcholinesterase inhibitor and their use in the treatment of cognitive disorders. The present invention further provides the pharmaceutical composition containing the said combination.Type: ApplicationFiled: August 14, 2017Publication date: May 30, 2019Applicant: SUVEN LIFE SCIENCES LIMITEDInventors: Ramakrishna NIROGI, Anil Karbhari SHINDE, Abdul Rasheed MOHAMMED, Pradeep JAYARAJAN, Gopinadh BHYRAPUNENI, Venkateswarlu JASTI
-
Patent number: 10294217Abstract: The present invention relates to compound of formula (I), or stereoisomers and pharmaceutically acceptable salts as muscarinic M1 receptor positive allosteric modulators. This invention also relates to methods of making such compounds and pharmaceutical compositions comprising such compounds. The compounds of this invention are useful in the treatment of various disorders that are related to muscarinic M1 receptor.Type: GrantFiled: July 19, 2016Date of Patent: May 21, 2019Assignee: Suven Life Sciences LimitedInventors: Ramakrishna Nirogi, Anil Karbhari Shinde, Abdul Rasheed Mohammed, Ramkumar Subramanian, Vijay Sidram Benade, Gopinadh Bhyrapuneni, Venkateswarlu Jasti
-
Publication number: 20180244655Abstract: The present invention relates to compound of formula (I), or stereoisomers and pharmaceutically acceptable salts as muscarinic M1 receptor positive allosteric modulators. This invention also relates to methods of making such compounds and pharmaceutical compositions comprising such compounds. The compounds of this invention are useful in the treatment of various disorders that are related to muscarinic M1 receptor.Type: ApplicationFiled: July 19, 2016Publication date: August 30, 2018Applicant: Suven Life Sciences LimitedInventors: Ramakrishna Nirogi, Anil Karbhari Shinde, Abdul Rasheed Mohammed, Ramkumar Subramanian, Vijay Sidram Benade, Gopinadh Bhyrapuneni, Venkateswarlu Jasti
-
Patent number: 10005711Abstract: The present invention relates to a process suitable for adoption to large scale manufacture of 1-isopropyl-3-{5-[1-(3-methoxypropyl)piperidin-4-yl]-[1,3,4]oxadiazol-2-yl}-1H-indazole oxalate of formula (I), which is a selective 5-HT4 receptor ligand intended for the symptomatic treatment of Alzheimer's disease and other disorders of memory and cognition like Attention deficient hyperactivity, Parkinson's and Schizophrenia.Type: GrantFiled: October 23, 2014Date of Patent: June 26, 2018Assignee: SUVEN LIFE SCIENCES LIMITEDInventors: Ramakrishna Nirogi, Abdul Rasheed Mohammed, Venkateswarlu Jasti
-
Publication number: 20180155302Abstract: The present invention relates to compound of formula (I), or stereoisomers and pharmaceutically acceptable salts as muscarinic M1 receptor positive allosteric modulators. This invention also relates to methods of preparing such compounds and pharmaceutical compositions comprising such compounds. The compounds of this invention are useful in the treatment of various disorders that are related to muscarinic M1 receptor.Type: ApplicationFiled: June 8, 2016Publication date: June 7, 2018Inventors: Ramakrishna Nirogi, Abdul Rasheed Mohammed, Anil Karbhari Shinde, Shankar Reddy Gagginapally, Venkateswarlu Jasti
-
Patent number: 9957257Abstract: The present invention relates to compounds of formula (I), including their stereoisomers and pharmaceutically acceptable salts. This invention also relates to methods of making such compounds and pharmaceutical compositions comprising such compounds. The compounds of this invention are useful in the treatment of various disorders that are related to 5-hydroxytryptamine 4 (5-HT4) receptor.Type: GrantFiled: January 7, 2016Date of Patent: May 1, 2018Assignee: SUVEN LIFE SCIENCES LIMITEDInventors: Ramakrishna Nirogi, Anil Karbhari Shinde, Abdul Rasheed Mohammed, Sangram Keshari Saraf, Narsimha Bogaraju, Ramkumar Subramanian, Pradeep Jayarajan, Gopinadh Bhyrapuneni, Venkateswarlu Jasti
-
Patent number: 9951045Abstract: The present invention relates to novel indazole compounds of the Formula (I), wherein, R1 is alkyl or cycloalkyl; (Formula II) including their stereoisomers and their pharmaceutically acceptable salts. This invention also relates to methods of making such compounds and pharmaceutical compositions comprising such compounds. The compounds of this invention are useful in the treatment of various disorders that are related to 5-Hydroxy-tryptamine 4 (5-HT4) receptor agonists.Type: GrantFiled: February 24, 2014Date of Patent: April 24, 2018Assignee: SUVEN LIFE SCIENCES LIMITEDInventors: Ramakrishna Nirogi, Abdul Rasheed Mohammed, Anil Karbhari Shinde, Shankar Reddy Gagginapally, Venkateswarlu Jasti